Comparative Pharmacology
Head-to-head clinical analysis: ACTAHIST versus SEMPREX D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTAHIST versus SEMPREX D.
ACTAHIST vs SEMPREX-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
1.34 mg (one capsule) orally twice daily.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
None Documented
None Documented
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination